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Summary
We used a phage expression library of cDNAs from metastatic breast carcinoma to identify protein domains that bind to
the vasculature of the lung, a frequent site of breast cancer metastasis. We found that one protein domain selectively
targeted phage as well as cells to the lung. This domain is part of the protein metadherin, shown by gene expression
profiling to be overexpressed in metastatic breast cancer. Immunostaining revealed that metadherin is overexpressed in
breast cancer tissue and breast tumor xenografts. Antibodies reactive to the lung-homing domain of metadherin and
siRNA-mediated knockdown of metadherin expression in breast cancer cells inhibited experimental lung metastasis,
indicating that tumor cell metadherin mediates localization at the metastatic site.
Introduction many of the factors that contribute to organ-specific metastasis
have yet to be elucidated.
To identify tumor cell surface molecules that mediate breastTumor metastasis is a complex, multistep process in which
cancer metastasis, we have used in vivo phage screening. Thiscancer cells detach from the original tumor mass and establish
screening method has been used by our group to identify pep-metastatic foci at organ-specific sites (Fidler, 2001). The location
tides and proteins that are capable of mediating selective inof the metastatic site depends on the particular type of cancer
vivo localization of phage to individual organs as well as tumorsand stage of disease. For example, breast cancer spreads first
and that reveal tissue-specific vascular differences (Arap et al.,to the lungs and liver (Kamby et al., 1987; Rutgers et al., 1989;
1998, 2002; Laakkonen et al., 2002; Pasqualini and Ruoslahti,Tomin and Donegan, 1987). Later in the disease, breast cancer
1996; Porkka et al., 2002; Rajotte et al., 1998).
spreads to the central nervous system and bone (Amer, 1982; In this study, we isolated from phage expression libraries
Boogerd, 1996). The metastatic phase of the disease is devasta- of breast carcinoma cDNAs a domain in a protein we call met-
ting, given that conventional treatments are usually ineffective adherin (for metastasis adhesion protein) that causes the phage
and patients typically survive only a few years after diagnosis to home specifically to lung microvasculature after intravenous
(Harris et al., 1997). injection. We show that the lung-homing domain of metadherin
Several factors affect the location and growth of metastases. is extracellular. Antibodies to metadherin revealed high amounts
of metadherin throughout human breast tumors and breast tu-Depending on the bloodflow pattern from the primary tumor,
mor xenografts while drastically lower levels of metadherin werecertain tumor cells are carried preferentially to particular organs
present in normal breast tissue. We also show that antibodies(Weiss, 1992). While in circulation, some tumor cells selectively
reactive to the lung-homing domain of metadherin inhibitedrecognize particular endothelial cell surface molecules that me-
experimental breast cancer lung metastasis, as did siRNA-medi-diate cell adhesion to specific organs (Abdel-Ghany et al., 2001;
ated knockdown of metadherin expression. These results sug-Cheng et al., 1998; Johnson et al., 1993). The arrest of tumor
gest that metadherin plays an important role in breast cancercells at the metastatic site, be it through mechanical trapping
metastasis.
in small capillaries or through adhesive interactions with the
endothelium, is a necessary step for tumors to establish at a Results
secondary site (Chambers et al., 2002; Orr and Wang, 2001).
Once the tumor cells have seeded the target organ, the local Identification of cDNA clones by phage display
microenvironment influences whether or not a particular cancer To identify candidate cell adhesion proteins that mediate breast
cancer metastasis, we used an in vivo phage screening ap-cell will proliferate (Fidler, 2001; Radinsky, 1995). Unfortunately,
S I G N I F I C A N C E
Adhesive interactions with the endothelium have been shown to contribute to the localization and growth of tumors at particular
secondary sites in experimental animals. In this report, we show that metadherin, a protein greatly overexpressed in breast cancers,
mediates lung-specific dissemination of metastatic cells. Independent microarray data have identified high metadherin gene
expression as a prognostic indicator of clinical metastasis in human breast cancer patients. Our results provide a possible mechanistic
explanation for the clinical findings. Our demonstration that metastasis can be inhibited by blocking the lung-homing domain of
metadherin with an antibody or by reducing metadherin expression identifies metadherin as a candidate target for therapeutic
intervention in breast cancer and perhaps other cancers as well.
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Figure 1. Homing specificity of metadherin
phage
A: Metadherin (closed bars) and nonrecombi-
nant (open bars) phage titers recovered from
lung, pancreas, breast, skin, kidney, brain, and
liver after injection into the tail vein of Balb/c
mice and circulation for 5 min. Error bars repre-
sent mean SD for 2–7 experiments per variable.
B: Metadherin (closed bars) and nonrecombi-
nant (open bars) phage titers recovered from
lung, pancreas, breast, skin, kidney, brain, liver,
and bone (tibia) after injection into the left ventri-
cle of the heart of Balb/c mice and circulation
for 5 min. Error bars represent mean  SEM for
2–5 experiments per variable.
C: Confocal projections of anti-phage immuno-
stained lungs from mice co-injected with fluo-
rescein-labeled tomato lectin (green) and either
metadherin phage (T7-metadherin) or T7-415
nonrecombinant phage (T7-Control). Control
lungs were from noninjected mice (lectin
phage), mice injected with lectin alone (lectin
phage), or mice injected only with metadherin
phage (lectinphage). Anti-phage antibody
was detected with Alexa 594 goat anti-rabbit
IgG antibody (red). Nuclei were stained with
DAPI (blue). The scale bars correspond to 50 m,
except in panels 1–6, where the scale bars corre-
spond to 10 m.
proach. We selected the highly metastatic, Balb/c-derived 4T1 (Altschul et al., 1997), we found one cDNA clone (GenBank
mammary tumor cell line to study tumor metastasis because accession number AY082966) that encoded the putative full-
4T1 cells and human mammary adenocarcinomas share similar length human protein corresponding to the phage clone. The
sites of metastasis (Aslakson and Miller, 1992; Dexter et al., GenBank entry refers to the protein as “LYRIC” and describes it
1978; Miller et al., 1983). Human breast cancer spreads first to as a putative CEACAM1-associated protein in colon carcinoma.
the lungs in 24%–77% of the cancers and to the liver in 22%– These observations remain unpublished. Based on our results
62% (Kamby et al., 1987; Rutgers et al., 1989; Tomin and Don-
egan, 1987). Similarly, 4T1 spreads in mice to the lungs and
liver in 95% and 75% of the cancers, respectively (Pulaski
and Ostrand-Rosenberg, 1998). We used the 4T1 cells to pre-
pare a cDNA library enriched in transcripts that encode secreted
and transmembrane proteins potentially involved in metastasis.
The 4T1 phage library was injected intravenously, and phage
that localized to the lungs were isolated. After three rounds of
selecting for lung-homing phage clones, 32 clones were initially
isolated. We tested individual phage clones for their ability to
specifically bind to lung vasculature. One of the five lung-spe-
cific clones we identified encoded a fragment of a protein re-
cently deposited into GenBank (accession numbers AAL92861
and AAP30791).
The selected phage, when intravenously (i.v.) injected into
mice and allowed to circulate for 5 min, bound to lungs almost
20-fold more than control phage (Figure 1A). In contrast, similar
numbers of the selected phage and control phage accumulated
in pancreas, breast, skin, kidney, brain, and liver. When injected
into the left ventricle of the heart in mice, significantly more
selected phage accumulated in the lungs, pancreas, kidney,
brain, and liver than control phage (Figure 1B). Similar numbers Figure 2. Sequence analysis of metadherin
of selected phage and control phage accumulated in breast, A: Amino acid sequence of metadherin’s lung-homing domain. This domain
corresponds to residues 378–440 of the full-length mouse metadherinskin, and bone. The selected phage colocalized with blood ves-
protein.sels in the lungs (Figure 1C).
B: Hydrophobicity analysis of metadherin, using a window size of 9 amino
acids.
cDNA cloning and membrane topology of metadherin C: Layout of the full-length metadherin protein. TM denotes the location of
The deduced amino acid sequence of the lung-homing domain the putative transmembrane domain. The numbers denote the position of
amino acids in the metadherin protein.of the lung-homing phage is shown in Figure 2A. Using BLAST
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Figure 3. Lung-homing domain of metadherin is extracellular
A: HEK293T cells expressing full-length myc-tagged metadherin, myc-vimen-
tin, or myc-pCMV were analyzed by flow cytometry. Anti-myc antibodies
were applied to the cells and detected with a PE-labeled secondary Ab.
B: Rabbit IgG, anti-Bcl2 polyclonal Ab (Bcl2), anti-integrin 51 polyclonal
antibody (Integrin 51), or anti-metadherin(378-440) (metadherin) was applied
to nonpermeabilized 4T1 tumor cells and detected with a FITC-labeled
secondary Ab. Control cells were stained with FITC-labeled secondary Ab
and propidium iodide alone (FITC/PI only).
Figure 4. Metadherin expression in 4T1 tumor cells
A: Immunoblot of endogenous metadherin. Lanes 1 and 4, 4T1 cell extract;
lane 2, KRIB cell extract; lane 3, MDA-MB-435 cell extract. Immunoblot de-
tection of metadherin was performed with anti-metadherin(378-440) (lanes 1–3).that show the importance of this lung-homing protein in breast
Immunoblot detection of an unrelated protein, Clone D2, was performedcancer metastasis, we have named this protein metadherin (me-
with anti-Clone D2 polyclonal antibody (lane 4).tastasis adhesion protein). We used a reported mouse cDNA
B: Confocal projection of permeabilized 4T1 cells stained with anti-metadh-
homolog of metadherin (GenBank accession number AK029915) erin(378-440). Scale bar corresponds to 50 m.
to design oligonucleotides and amplified the full-length 1740 bp C: Confocal sections (0.15 m thick; panels 1–3) of nonpermeabilized 4T1
cells stained with anti-metadherin(378-440).mouse metadherin cDNA by reverse transcription-polymerase
D and E: Nonpermeabilized 4T1 cells stained with anti-metadherin(378-440) thatchain reaction.
was pre-incubated with excess metadherin(378-440) peptide (D, panels 1–3) orAnalysis of the hydrophobic regions of metadherin (Kyte excess control peptide (E, panels 1–3). In B–E, anti-metadherin(378-440) was
and Doolittle, 1982) revealed that amino acid residues 52–74 detected with Alexa 594 goat anti-rabbit IgG antibody (red). Nuclei were
stained with DAPI (blue). Images in D and E were captured using an invertedencode a putative transmembrane domain (Figure 2B). We did
fluorescent microscope. The scale bars in C–E correspond to 5 m.not find any domains in metadherin that were similar to other
known proteins. Using a hidden Markov model to detect mem-
brane helices and predict transmembrane topology in proteins
(Glasgow, 1998; Krogh et al., 2001), we found that metadherin
cells at the cell surface where it would be available to bindwas predicted to be a type II transmembrane protein with an
to vascular targets during metastasis. An antibody against aextracellular lung-homing domain. To confirm this prediction,
cytoplasmic protein (Bcl-2) and rabbit IgG did not bind to thewe subcloned a c-myc epitope into the lung-homing domain of
surface of nonpermeabilized 4T1 cells, while the cells werethe metadherin cDNA, as shown in Figure 2C. This myc-tagged
strongly positive for integrin 51 (Figure 3B).cDNA was expressed in HEK293T cells, and these cells were
In 4T1 tumor cell extracts, anti-metadherin(378-440) detectedthen stained with anti-myc antibodies. Using flow cytometry,
proteins with apparent molecular weights of approximately 80we observed that intact myc metadherin-expressing cells were
kDa, 75 kDa, and 55 kDa (Figure 4A, lane 1). KRIB and MDA-labeled with anti-myc antibodies (Figure 3A), indicating that the
MB-435 cell extracts also contained the 80 kDa and 75 kDalung-homing domain of metadherin was extracellular. No cell
proteins (Figure 4A, lanes 2 and 3, respectively). A control,surface labeling was detected in vector-transfected cells or non-
affinity-purified polyclonal antibody reactive to a nonrelated pro-permeabilized cells expressing the intracellular protein myc-
tein (Clone D2) did not detect the anti-metadherin(378-440) immuno-vimentin (Figure 3A). Anti-myc antibodies stained the myc vi-
reactive bands (Figure 4A, lane 4). The 80 kDa and 55 kDamentin-expressing cells when permeabilized, which confirms
proteins detected by anti-metadherin(378-440) were also producedthe expression of myc-vimentin, and permeabilized cells ex-
by an in vitro transcription and translation reaction using anpressing vector alone were not stained with anti-myc antibodies
epitope-tagged metadherin cDNA as template (data not shown);(data not shown).
this suggests that the 55 kDa protein may be a degradation
product of metadherin.Metadherin expression in tumor cells and tumors
In fixed and permeabilized 4T1 cells, metadherin immunore-We also raised rabbit antibodies reactive to the lung-homing
activity localized throughout the cytoplasm (Figure 4B). In non-domain of metadherin to study endogenous metadherin in tumor
permeabilized cells, the staining was concentrated at the edgescells and tumors. These antibodies bound to nonpermeabilized
of the cells (Figure 4C). Controls showed that pre-incubation4T1 cells in flow cytometry (Figure 3B). This result confirms the
presence of the lung-homing domain of metadherin on tumor of anti-metadherin(378-440) with the metadherin(378-440) lung-homing
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metadherin(378-440) showed high amounts of metadherin through-
out the tumor (Figure 5G). In contrast, we did not detect any
cytoplasmic or cell surface-associated metadherin in normal
human breast tissue, but nuclear staining was present (Figure
5J). The cell surface staining of breast cancer tissue could be
inhibited with the metadherin(378-440) peptide (Figure 5H), but not
with control peptide (Figure 5I). Neither peptide inhibited nuclear
staining (Figures 5H, 5I, 5K, and 5L). The human sections were
paraffin embedded and processed with heat-induced target re-
trieval. Apparently, the antibody nonspecifically stains nuclei
in such sections. In frozen tissue sections of normal mouse
mammary tissue, we found specific metadherin staining at the
apical surface of epithelial cells lining ducts of the mammary
glands (Figures 5M and 5N), and a small amount of metadherin
was dispersed through the mammary fat pad. We detected
no metadherin in the spleen, kidney, lung, or skin, but minute
amounts were seen in the liver. Purkinje neurons in the early
postnatal and adult cerebellum were strongly positive for met-
adherin staining (data not shown). Tissue array slides of human
breast tissue and breast adenocarcinomas were also stained
with anti-metadherin(378-440). We detected strong anti-metadh-
erin(378-440) staining throughout the tissue sections in 17 out of
31 breast adenocarcinomas, while metadherin was absent in
18 out of 20 samples of normal breast tissue. The other two
normal breast tissue samples stained positive for metadherin
at epithelial cells lining ducts of the mammary glands. These
immunostaining results show that metadherin is selectively
overexpressed in tumors.
Effect of metadherin expression on the localization
of injected cells
To test the effect of metadherin on tissue distribution of i.v.-
Figure 5. Metadherin expression in tumor xenografts and human breast
injected tumor cells, we studied HEK293T cells transiently trans-cancer
fected with metadherin. The cells were cotransfected withMDA-MB-435 breast adenocarcinoma (A–C) or KRIB osteosarcoma (D–F)
DsRed2 and metadherin, and DsRed2-positive cells were iso-tumor xenografts grown in nude Balb/c mice were analyzed by immuno-
staining. Sections were stained with either anti-metadherin(378-440) alone (A lated using fluorescence-activated cell sorting (FACS). The cells
and D) or anti-metadherin(378-440) pre-incubated with excess metadherin(378-440) were then i.v.-injected into mice. Fluorescent cells were de-
peptide (B and E) or excess control peptide (C and F). Sections of human tected in the blood vessels of lungs examined 2 hr after the
breast tumor (G–I) or normal human breast tissue (J–L) were stained with
injection; cell counting showed 22% more metadherin-trans-either anti-metadherin(378-440) alone (G and J) or anti-metadherin(378-440) pre-
fected cells than that of vector-transfected cells (Figures 6Aincubated with excess metadherin(378-440) peptide (H and K) or excess control
peptide (I and L). Sections of mouse breast tissue were stained with either and 6B; Student’s t test; p  0.001). We did not see significant
anti-metadherin(378-440) alone (M) or anti-metadherin(378-440) pre-incubated numbers of DsRed2 HEK293T cells in the brain, skin, liver,
with excess metadherin(378-440) peptide (N). In all panels, anti-metadherin(378-440) kidney, heart, spleen, or pancreas (Figure 6A). This result sup-was detected with Alexa 594 goat anti-rabbit IgG antibody (red) and nuclei
ports the phage homing data indicating that metadherin prefer-were stained with DAPI (blue). The confocal projections in A–N were cap-
tured using a confocal microscope. The scale bars correspond to 50 m. entially binds to lung vasculature. The relatively small incremen-
tal effect of metadherin overexpression on the lung localization
of HEK293T cells is probably due to endogenous expression
of metadherin by these cells, which immunoblotting showed to
peptide inhibited the staining (Figure 4D), whereas a control be about 45% of that in the 4T1 cells (data not shown).
peptide did not (Figure 4E).
We detected strong metadherin staining in sections of MDA- Anti-metadherin and metadherin siRNA inhibit
MB-435 and KRIB tumor xenografts (Figures 5A and 5D), which 4T1 lung metastasis
are two tumor models known to generate lung metastases (Ber- To gain information on the role of metadherin in metastasis,
lin et al., 1993; Price et al., 1990). The anti-metadherin immuno- we decided to inhibit metadherin activity in the 4T1 cells with
staining was specific, since pre-incubation of antibody with the antibodies reactive to the lung-homing domain of metadherin.
metadherin(378-440) lung-homing peptide (Figures 5B and 5E) in- When co-injected with the 4T1 cells, anti-metadherin(378-440) inhib-
hibited the staining and control peptide (Figures 5C and 5F) had ited lung metastasis by about 40% (Figure 7, p  0.01), com-
no inhibitory effect. Subcutaneous tissue or skin adjacent to pared to 4T1 cells treated with rabbit IgG. In a separate experi-
the tumors showed no anti-metadherin staining (e.g., Figure 5D, ment, we did not observe any difference between the growth
lower left corner). of mammary fat pad tumors formed from 4T1 cells pretreated
with the anti-metadherin(378-440) or rabbit IgG (data not shown).Several human breast cancer sections stained with anti-
368 CANCER CELL : APRIL 2004
A R T I C L E
Figure 7. Anti-metadherin antibodies inhibit lung metastasis
Number of lung metastases from mice injected with 4T1 cells that were
treated with anti-metadherin(378-440), rabbit IgG, or PBS. Average number of
metastases in each group is denoted with a horizontal line. The percent
difference in average number of metastases between groups is denoted
above the brackets, with significance measured using a one-tailed Stu-
dent’s t test (*p  0.02, **p  0.01).
Using flow cytometry, the effects of metadherin-reactive
siRNA and scrambled-siRNA on cell growth and viability were
assessed. In 4T1 cells cotransfected with EGFP and met-
adherin-reactive siRNA or scrambled-siRNA expression plas-
Figure 6. HEK293Ts overexpressing metadherin localize to lung mids, we did not detect any significant difference in propi-
A: DAPI-stained (blue) lung sections from mice injected with HEK293T cells dium iodide staining between the EGFP-positive populations
that were cotransfected with a DsRed2 expression vector (red) and either from the metadherin-reactive siRNA or scrambled-siRNA cells
metadherin-pCMV or expression vector alone. Pancreas, skin, kidney, brain,
(4.52% versus 5%, see Supplemental Figure S1 at http://www.liver, and spleen sections from mice injected with HEK293T cells that were
cancercell.org/cgi/content/full/5/4/365/DC1). This suggestedtransfected with a DsRed2 expression vector (red) and metadherin-pCMV.
The scale bars correspond to 100 m. metadherin-reactive siRNA did not affect 4T1 cell viability under
B: Number of DsRed2-positive cells per viewing field in the lung sections these conditions. In addition, the number of EGFP-positive cells
(n 	 75; one-tailed Student’s t test; *p  0.001).
in the metadherin-reactive siRNA and scrambled-siRNA trans-
fected 4T1 cells was not significantly different, suggesting the
metadherin-reactive siRNA plasmid did not inhibit cell growth
during the 2 day transfection period (9.55% versus 9.95%, Sup-As a second approach, we measured the metastatic poten-
plemental Figure S1). Also, we counted the number of cellstial of breast cancer cells expressing reduced levels of metadh-
before and 2 days after transfecting the siRNA expression plas-erin. As shown in Figure 8A, siRNA reactive to metadherin, but
mids and did not see any significant effect of the metadherin-not siRNA to GAPDH or scrambled-siRNA, was able to knock
siRNA on the growth rate of the cells (data not shown).down expression of transfected myc-metadherin in HEK293T
Immunostaining confirmed that metadherin-siRNA cells ex-cells. We were unable to generate stable cell lines that ex-
pressed less metadherin (Figure 8D, 1 and 2) than scrambled-pressed reduced levels of metadherin because metadherin ex-
siRNA cells (Figure 8D, 3 and 4). Using FACS, we isolated EGFP-pression levels returned to normal after 2 weeks. Instead, we
positive cells that excluded propidium iodide to select for viablecoexpressed green fluorescent protein (EGFP) and the metadh-
siRNA-transfected cells (Figure 8D, 5–8). When injected intoerin-reactive siRNA or scrambled-siRNA in 4T1 cells and se-
mice, the 4T1 cells expressing metadherin-reactive siRNAlected for siRNA-transfected cells by FACS. The transfection
formed about 80% fewer experimental lung metastases thanwith metadherin-siRNA did not affect the expression of -actin
cells expressing scrambled-siRNA (Figure 8E, Student’s t test,or the type II transmembrane protein, transferrin receptor (Figure
p  0.001).8B). However, metadherin protein expression in metadherin-
siRNA cells was reduced by about 40% relative to the scram-
Discussionbled-siRNA cells (Figure 8B). Measured by real-time PCR, met-
adherin-siRNA cells expressed about 40% less metadherin
We report here that a protein, metadherin, is overexpressed inmRNA than the scrambled-siRNA cells, when metadherin mRNA
levels were normalized to -actin mRNA levels (Figure 8C). breast tumors and binds to lung vasculature through a C-ter-
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Figure 8. siRNA reactive to metadherin mRNA inhibits lung metastasis
A: Anti-myc immunoblot of HEK293T cell extracts expressing myc-tagged metadherin and siRNA reactive to GAPDH or metadherin, or scrambled-siRNA.
B: Immunoblot quantitation of -actin, transferrin receptor, or metadherin protein levels in 4T1 cells expressing siRNA reactive to metadherin or scrambled-
siRNA. The arrow in B denotes the 80 kDa metadherin protein band quantified by densitometry.
C: Quantitation of metadherin mRNA in 4T1 cells expressing siRNA reactive to metadherin or scrambled-siRNA. The relative amount of metadherin mRNA
was normalized to the abundance of -actin mRNA, also detected by real-time PCR. Error bars represent mean  SD.
D: 4T1 cells were cotransfected with an EGFP expression vector and a vector expressing siRNA reactive to metadherin (panels 1, 2, 5, and 6) or scrambled-
siRNA (panels 3, 4, 7, and 8). The cells were sorted by FACS to select for EGFP-expressing cells (Post sort). Nonsorted cells (No sort; panels 1–4) and postsorted
cells (panels 5–8) were stained with anti-metadherin(378-440). Panels 2, 4, 6, and 8 show the EGFP-expressing cells (green) displayed in panels 1, 3, 5, and 7,
respectively. In all panels, anti-metadherin(378-440) was detected with Alexa 594 goat anti-rabbit IgG antibody (red). Nuclei were stained with DAPI (blue).
The scale bars correspond to 50 m.
E: siRNA reactive to metadherin transcripts inhibits 4T1 cell experimental lung metastasis. Values are expressed as the number of tumor foci per 10,000 cells
injected. Bars represent mean  SEM (one-tailed Student’s t test; ***p  0.001). In C and E, percentages indicate relative suppression compared to control
group.
minal segment in the extracellular domain. We also show that Tissue-specific expression of vascular markers is not limited to
blocking the lung-homing domain with antibodies or inhibiting lung vasculature; recent data suggest that each tissue puts a
the expression of metadherin with siRNA can inhibit breast can- specific signature on its vasculature (Ruoslahti, 2002). Thus, the
cer metastasis. These results identify metadherin as a potential binding of tumor cells to tissue-specific vascular markers may
mediator of cancer metastasis. play a role in selective tumor metastasis to other tissues as
Metadherin appears to detect a specific marker of lung vas- well.
culature. Metadherin phage accumulated in lung vasculature Metadherin appears to primarily mediate metastasis to one
after either tail-vein or intracardiac injection, suggesting that of the four sites commonly affected by human breast cancer:
among the various vascular beds, it primarily binds to lung
the lungs. The fact that metadherin phage primarily targeted
endothelium. In this regard, metadherin is similar to lung-spe-
the lungs after either intravenous or intracardiac injection andcific homing peptides isolated by in vivo phage display (Rajotte
was not detected in substantial amounts in the liver, brain, orand Ruoslahti, 1999) and antibodies that specifically bind to
bone suggests that metadherin mediates specific adhesion tolung vasculature (McIntosh et al., 2002). The ability of metadh-
lung vasculature, even after passing through capillary networkserin phage to specifically target lung vasculature suggests that
of other organs. The ability of metadherin phage to accumulateamong the various vascular beds, the molecule(s) metadherin
in the lungs even after intracardiac injection suggests that met-binds (“metadherin receptor”) is primarily expressed on lung
endothelium. The identity of the receptor is currently unknown. adherin also promotes selective binding of tumor cells to lung
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vasculature, rather than helping them adhere to the first capillary Metadherin is a potential target for tumor diagnosis and
preventative therapy. Given the cell surface localization of met-bed the cells encounter.
Metadherin may be important to the pathogenesis of cancer. adherin in tumor cells and the discrete overexpression of met-
adherin in primary tumors, therapeutics that target metadherinWe found high expression of metadherin in cultured tumor cells,
and its expression was higher in both experimental and clinical might prove to be selective for metastasis-prone tumors. Our
results showing the antimetastatic activity of anti-metadherinbreast cancers than in normal breast tissue and in other normal
tissues, as detected with specific metadherin antibodies. The antibodies and siRNA reactive to metadherin mRNA suggest
that antibody or siRNA-based therapies that target metadherinonly exception to the relatively low expression in the normal
tissues we studied were the Purkinje cells in the cerebellum; might be effective in preventing certain tumors from metasta-
sizing.metadherin may have a specific function in these cells.
A recent gene expression profiling study on breast cancer
Experimental procedurespatients revealed that metadherin is overexpressed in many
metastatic breast cancers. van ’t Veer et al. (2002) found that
Cell lines, mice, and tumors
metadherin mRNA expression levels (described as GenBank 4T1, a cell line derived from a Balb/c breast adenocarcinoma, was obtained
entry AK000745) in breast cancer patients were significantly from ATCC and maintained as described by Pulaski and Ostrand-Rosenberg
correlated with a poor prognosis due to metastasis. Out of (1998). MDA-MB-435 and KRIB cell lines were maintained as described
before (Laakkonen et al., 2002). Nude Balb/c mice were subcutaneously25,000 genes analyzed, metadherin was ranked 25th when corre-
injected with 1 
 106 tumor cells and kept for 5 weeks (KRIB) or 10 weekslating gene expression levels with metastasis. Most of the pa-
(MDA-MB-435). Tumors were then removed, frozen in OCT embedding me-tients who expressed high levels of these “poor prognosis”
dium (Tissue-Tek, Elkhart, IN), and sectioned. The Burnham Institute Animal
classified genes developed distant metastases within 5 years Research Committee approved the animal experimentation.
of observation. Thus, metadherin is overexpressed in breast
cancer both at the protein and mRNA levels and is associated Phage library and screening
A cDNA library was prepared from membrane bound polyribosomal mRNAwith increased malignancy of these cancers. Our results suggest
of 4T1 cells. Briefly, RNA from membrane bound polysomes of 3.2 
 108that the association of metadherin overexpression with poor
4T1 cells was prepared using the methods described by Mechler (1987).prognosis of breast cancer is due to an ability of metadherin to
Approximately 1 g of this RNA was used to generate 6 g of amplifiedspecifically promote tumor metastasis to the lungs.
antisense mRNA (aRNA), using the methods described by Luo et al. (1999).
There are other examples of adhesive interactions that are Using aRNA as template, mRNA was synthesized as described by Luo et
required in order for lung metastases to form. Dipeptidyl dipepti- al. (1999), except the primer, 5-TTNNNNNN-3, was used instead of random
hexamer primer, and methylated dNTPS were used instead of dNTPs. Adase IV on lung endothelial cells was found to be an adhesion
cDNA library was prepared from the mRNA, as described in the manufactur-receptor for fibronectin on metastasizing breast and prostate
er’s protocol (OrientExpress Random Primer cDNA synthesis kit; Novagen,carcinoma cells in a mouse model (Cheng et al., 1998; Johnson
Madison, WI).et al., 1993). In another mouse model, Ca2-sensitive chloride
T7 phage vectors, designed to express cDNA library-encoded proteins
channel, hCLCA2, expressed on lung endothelial cells was re- fused at the N terminus to phage 10B coat protein and to a myc epitope
ported to be a ligand for 4 integrins on metastasizing breast at the C terminus, were then assembled. Oligonucleotides encoding myc
cancer cells (Abdel-Ghany et al., 2001; Elble et al., 1997). Most epitopes in all three reading frames, internal EcoRI and HindIII restriction
enzyme cleavage sites and flanking EcoRI/HindIII adapters, were synthe-recently, the secreted chemokine, CXCL12, which is highly ex-
sized. The oligonucleotides were then individually phosphorylated, annealed,pressed in the lung, liver, and lymph nodes, was shown to bind
and ligated to EcoRI/HindIII-digested T7Select 1-2a, 1-2b, or 1-2c vectorto CXCR4 receptors on the surface of metastasizing breast
arms (Novagen) to generate myc epitope phage vectors.
cancer cells (Muller et al., 2001). Moreover, interfering with only To prevent myc epitope expression in phage vectors that were unsuc-
one of these interactions was sufficient to inhibit metastasis cessfully ligated to cDNA during library construction, a linker encoding stop
(Abdel-Ghany et al., 2001; Cheng et al., 1998; Muller et al., 2001). codons in all three reading frames was inserted upstream of the myc epitope
and downstream of the 10B coat protein in the phage vector. Oligonucleo-Although there is no evidence available on the significance of
tides encoding stop codons in all three reading frames were synthesized,these interactions in breast cancer, it seems that multiple inter-
phosphorylated, annealed, and ligated to EcoRI/HindIII-digested myc epi-actions of cell adhesion molecules and growth factor receptors
tope phage vectors to form myc-T7 vectors. A map of the myc epitope phagemay be required for the attachment and growth of circulating
vector is shown in Supplemental Figure S2 at http://www.cancercell.org/cgi/
tumor cells in the lung. Similar mechanisms based on unique content/full/5/4/365/DC1. The cDNA libraries were then ligated to EcoRI/
vascular addresses may play a role in organ-specific metastasis HindIII-digested myc-T7 vector, phage were packaged, and libraries were
amplified in E. coli BLT5615 cells (according to the manufacturer’s protocol;to other organs.
Novagen). As measured by plaque assay, the library contained 4.7 
 106The importance of metadherin in tumor cell metastasis might
primary recombinants.not only be limited to breast cancer. Using SAGEmap (Lal et
Phage clones that expressed cDNA inserts with open reading framesal., 1999; Lash et al., 2000), a component of The Cancer Genome
were enriched by three rounds of selection with anti-myc mAb (3.1 g/ml
Anatomy Project at the National Center for Biotechnology Infor- MAB8864; Chemicon, Temecula, CA) bound to rat anti-mouse IgG1 mag-
mation, we found that metadherin is significantly overexpressed netic beads (3.1 l per 1 ml of buffer; Miltenyi Biotec, Auburn, CA). Selections
not only in breast cancers, but also in cancers of the brain and were performed with 1011 plaque forming units (pfu) of phage in 10 ml of
Dulbecco’s phosphate buffered saline containing 0.5% bovine serum albu-prostate (p  0.05). This suggests that metadherin might also
min (PBSB). Phage were applied to a magnetized LS MACS column (Miltenyiplay a role in the metastasis of these cancers. Metadherin is
Biotec), washed with buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1%conserved among mammals, and with the BLAST algorithm
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate), eluted(Altschul et al., 1997), we found additional mouse and human
with PBSB after demagnetizing the column, and transferred to a second
metadherin-like molecules in the GenBank databases. It will be column for more washes. Phage were amplified in BLT5615 E. coli using the
important to determine what role, if any, these related molecules liquid lysate method after each anti-myc selection round and supernatants
clarified by centrifugation were supplied with 1% vol/vol of E. coli proteasemight play in cancer.
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inhibitors cocktail (P-8465; Sigma-Aldrich, St. Louis, MO). After three rounds polyclonal antibody reactive to a 175 kDa protein, Clone D2, was prepared
as described for anti-metadherin(378-440). Control immunoblots were performedof myc antibody sorting, over 90% of the phage clones in the 4T1 library
were found to contain open reading frame cDNA inserts. On average, the with anti-Clone D2 (0.1 g/ml) and goat anti-rabbit IgG-HRP (described
above).phage clones expressed protein fragments that were 75 amino acids long.
Ex vivo and in vivo screenings with the 4T1 phage library were performed For cell surface labeling, anti-metadherin(378-440), diluted to 20 g/ml in
ice-cold IMEM (Invitrogen) with 10% fetal bovine serum (FBS), was addedas previously described (Hoffman et al., 2004). Briefly, cell suspensions were
prepared from mouse lungs and incubated overnight at 4C with 109 pfu of to cells cultured on chamber slides and incubated for 1 hr on ice. The cells
were washed with IMEM and fixed with cold 4% parformaldehyde in PBS4T1 phage library. The cells were washed to remove unbound phage, and
for 15 min. Anti-metadherin antibodies were detected with Alexa 594 goatthe bound phage were rescued and amplified by adding BLT5615 E. coli.
anti-rabbit IgG (diluted 1:500 in PBS with 1% FBS and 3% goat serum).The amplified 4T1 phage library was applied to a lung cell suspension for
Slides were mounted with Vectashield fluorescence mounting medium (Vec-a second ex vivo selection round, as before. The ex vivo preselected phage
tor, Burlingame, CA). For permeabilized cell labeling, cells were first fixedpool (200 l, or approximately 109 pfu) was injected intravenously into
with 4% parformaldehyde (described above) and then treated with 0.1%2-month-old Balb/c mice through the tail vein, allowed to circulate for 5 min,
Triton X-100 in PBSB for 15 min. The cells were washed with PBSB andand heart-perfused with PBS to remove unbound intravascular phage. Cell
incubated with anti-metadherin(378-440) (diluted to 20 g/ml in IMEM with 10%suspensions of tissue were prepared by mechanical disruption and washed
FBS) for 1 hr at room temperature. Anti-metadherin(378-440) was detected withto remove unbound phage, and the bound phage were rescued and amplified
Alexa 594 goat anti-rabbit IgG, as described above.by adding BLT5615 E. coli. The phage pool was reinjected into Balb/c mice,
Paraffin-embedded human tissue sections (Spring Biosciences, Fre-and the cycle repeated twice. For each selection round, the number of phage
mont, CA) and breast adenocarcinoma tissue array sections (InnoGenex,recovered from the tissue was normalized to the number of injected phage
San Ramon, CA; NCI, Frederick, MD) were deparaffinized and then treatedand tissue mass. After three rounds of in vivo selections, cDNA inserts were
with Target Retrieval Solution (according to the manufacturer’s instructions;sequenced from 32 phage clones as described before (Hoffman et al., 2004).
DAKO, Carpinteria, CA). For immunofluorescence imaging, the sections were
stained as described above, except PBSB was substituted for 0.5% BlockingCloning of full-length metadherin cDNA
Reagent (NEN Life Sciences, Boston, MA) in 0.1 M Tris/150 mM NaCl.The following primers were synthesized to amplify the full-length mouse
The tissue array sections were stained as described above, except anti-metadherin cDNA: 5-ACCATGGCTGCACGAAGCTGGCAGGACGAGCTG-3
metadherin(378-440) was detected with the EnVision  System (according toand 5-TCACGTTTCCCGTCTGGCCTTTTTCTTCTTTTTTA-3. RNA was iso-
the manufacturer’s instructions; DAKO) and cells were counterstained withlated from 4T1 cells using a Total RNA Isolation Kit (Qiagen, Valencia, CA).
hematoxylin (DAKO). To determine specificity, anti-metadherin(378-440) (20The metadherin cDNA was amplified by RT-PCR using a Superscript
g/ml) was pre-incubated overnight with 200 g/ml recombinant metadherinOne-Step RT-PCR Kit for Long Templates (according to manufacturer’s
lung-homing protein or unrelated recombinant control protein (72 aminoprotocol; Invitrogen, Carlsbad, CA) and subcloned into the TOPO-TA vector,
acid, lung-homing Clone D2) in blocking buffer before immunostaining thepcDNA3.1-V5/His (according to the manufacturer’s protocol; Invitrogen).
sections.A myc epitope was added to metadherin protein by first inserting an
EcoRI restriction enzyme site in the metadherin cDNA after nucleotide 1222
FACS analysiswith a QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA).
Transiently transfected HEK293T cells expressing myc-vimentin, myc-met-Then, oligonucleotides encoding a myc epitope (EQKLISEEDL) and flanking
adherin, or myc-pCMV vector alone (Clontech) were detached from theirEcoRI adapters were synthesized, phosphorylated, and ligated into the
culture dishes by gently washing with PBS containing 1% BSA (PBSB). TheEcoRI-digested metadherin cDNA. The myc-metadherin cDNA was sub-
cells were then stained with anti-myc mAb (2 g/ml in PBSB; Chemicon)cloned into the pCMV vector (Clontech, Palo Alto, CA). Human myc-vimentin
for 20 min at 4C. The cells were washed with PBSB, stained with goat anti-cDNA was generated by reverse transcription-polymerase chain reaction,
mouse IgG PE-labeled antibody (4 g/ml in PBSB; Pharmingen, San Diego,using vimentin-specific primers and human mRNA as template, and then
CA), washed again with PBSB, fixed with 2% parformaldehyde in PBS,subcloned into the pCMV-Myc vector (Clontech, Palo Alto, CA).
resuspended in PBS, and analyzed using a FACScan flow cytometer (BD,
San Jose, CA).Antibodies, immunoblotting, and immunohistology
To analyze the 4T1 cells by FACS, the cells were detached from culture
Anti-T7 phage affinity purified antibody was previously described (Laakkonen
plates by incubating with PBS with 2 mM EDTA (PBSE) for 10 min. The cells
et al., 2002). A polyclonal antibody was generated in New Zealand White
were then washed with PBSB and incubated with 40 g/ml (in PBSB) of the
rabbits against the recombinant metadherin lung-homing domain that was
following antibodies: anti-Bcl2 (SL-492, Santa Cruz Biotechnology, Santa
fused to glutathione-S transferase. The initial immunization was done in
Cruz, CA), normal rabbit IgG (Sigma, St. Louis, MO), anti-integrin51 (Proteincomplete Freund’s adjuvant and boosters were with incomplete Freund’s G-purified from rabbit serum containing antibodies raised against human
adjuvant. The antibody was affinity purified on recombinant hexahistine- fibronectin receptor), and anti-metadherin(378-440). To detect bound antibodies,
tagged metadherin(378-440) peptide coupled to SulfoLink Gel (Pierce, Rockford, cells were incubated with goat anti-rabbit IgG-FITC (40 g/ml in PBSB;
IL) via a cysteine residue added to the amino terminus of the metadherin(378-440) Molecular Probes, Eugene, OR). After the final wash, the cells were resus-
peptide. pended with PBS containing 2 g/ml of propidium iodide (PI) and analyzed
Blood vessel localization of metadherin phage was examined by i.v. by FACS.
injection of 2.5 
 1010 pfu metadherin phage (in 200 l M9LB) into the tail
vein of a mouse. Blood vessels were visualized by co-injection of phage with HEK293T cell homing
200g of Lycopersicon esculentum (tomato) lectin conjugated to fluorescein. HEK293T cells were cotransfected with DsRed2 (Clontech) and either met-
The injected materials were allowed to circulate for 10 min. Lungs were adherin-pCMV or empty myc-pCMV vector. 2 days posttransfection, the
removed and frozen in OCT embedding medium (Tissue-Tek). cells were detached with PBSE and filtered through a 40 m nylon filter.
Tumor cell lysates were prepared in 2.5
 Laemmli’s sample buffer DsRed2-expressing cells were isolated using a FACS Vantage flow cyto-
(Laemmli, 1970) at a ratio of 106 cells per 150 l and subjected to SDS- meter (BD Biosciences, San Jose, CA). 2.5 
 105 DsRed2-positive cells
PAGE on 4%–20% acrylamide gradient gels. Proteins were transferred to PVDF were injected into the tail vein of nude Balb/c mice. Five mice were injected
membrane and immunoblots were performed with anti-metadherin(378-440) (0.1 with each cell type. After 2 hr, the mice were sacrificed, organs were removed
g/ml) and goat anti-rabbit IgG-HRP (diluted 1:10,000; Bio-Rad, Hercules, and fixed with 4% paraformaldehyde in PBS, and 10 m thick frozen tissue
CA) and developed using ECLplus chemiluminescence reagent (Amersham sections were prepared. For each lung section, three different fields were
Biosciences, Piscataway, NJ), according to the manufacturer’s instructions. counted. Clumps of DsRed2-positive cells with three or more cells were
The relative amount of metadherin detected by immunoblot was quantitated excluded from the count. Five sections per lung were counted.
using an AlphaImager (Alpha Innotech, San Leandro, CA). -actin was de-
tected with an anti-actin monoclonal antibody (10 g/ml, Chemicon). Trans- Tumor metastasis studies
ferrin receptor was detected with an anti-transferrin receptor polyclonal The 4T1 cells were detached from plates with PBSE, washed once with
PBS, resuspended to 5 
 105 cells/ml in PBS, and placed on ice. Anti-antibody (2 g/ml, Santa Cruz Biotech, Santa Cruz, CA). Affinity-purified
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V.L., Jr. (1993). Development of a novel spontaneous metastasis model ofmetadherin(378-440) or rabbit IgG (200 g) was added to 5 
 104 cells and the
human osteosarcoma transplanted orthotopically into bone of athymic mice.cells were then injected via the lateral tail vein into female Balb/c nu/nu
Cancer Res. 53, 4890–4895.mice. Animals were sacrificed 7 days after tumor cell injection. Lungs were
recovered and fixed with Bouin’s solution, and the tumor foci on the surface Boogerd, W. (1996). Central nervous system metastasis in breast cancer.
of the left lobe were counted under a dissecting microscope. Radiother. Oncol. 40, 5–22.
Chambers, A.F., Groom, A.C., and MacDonald, I.C. (2002). DisseminationsiRNA knockdown of metadherin expression
and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563–572.For the siRNA-mediated knockdown of metadherin expression, nucleotides
1597–1615 of the mouse metadherin cDNA (5-GTGCCACCGATGTTAC Cheng, H.C., Abdel-Ghany, M., Elble, R.C., and Pauli, B.U. (1998). Lung
AAG-3) were used as the target sequence. Oligonucleotides containing this endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of
target sequence were synthesized and subcloned into the pSilencer 3.0-H1 rat breast cancer cells via tumor cell surface-associated fibronectin. J. Biol.
plasmid (Ambion, Austin, TX) according to the manufacturer’s instructions. Chem. 273, 24207–24215.
4T1 cells were transfected with the metadherin or a negative control siRNA
Dexter, D.L., Kowalski, H.M., Blazar, B.A., Fligiel, Z., Vogel, R., and Heppner,pSilencer vector together with an EGFP-expression vector (Clontech), using
G.H. (1978). Heterogeneity of tumor cells from a single mouse mammarya 4:1 ratio of pSilencer to EGFP vectors. 2 days posttransfection, 4T1 cells
tumor. Cancer Res. 38, 3174–3181.that were labeled with EGFP and excluded propidium iodide were isolated
by FACS. 10,000 or 50,000 of these selected 4T1 cells in 100 l of PBS Elble, R.C., Widom, J., Gruber, A.D., Abdel-Ghany, M., Levine, R., Goodwin,
were injected into the tail vein of anesthetized nude Balb/c mice. The mouse A., Cheng, H.C., and Pauli, B.U. (1997). Cloning and characterization of lung-
lungs were harvested 22 days postinjection and fixed with Bouin’s solution. endothelial cell adhesion molecule-1 suggest it is an endothelial chloride
The tumor foci on the lung surface were counted under a dissecting micro- channel. J. Biol. Chem. 272, 27853–27861.
scope. Data were recorded as the number of tumor foci formed per 10,000
Fidler, I.J. (2001). Seed and soil revisited: contribution of the organ microenvi-cells injected. The levels of -actin and metadherin mRNA in siRNA-trans-
ronment to cancer metastasis. Surg. Oncol. Clin. N. Am. 10, 257–269.
fected cells were determined using a one-step RT-PCR RNA Amplification
Kit and LightCycler Instument (according to manufacturer’s protocol; Roche, Glasgow, J. (1998). Proceedings, Sixth International Conference on Intelli-
Indianapolis, IN). gent Systems for Molecular Biology: June 28–July 1, 1998, Montreal, Quebec
(Menlo Park, CA: AAAI Press).
GenBank accession number
Harris, J., Morrow, M., and Norton, L. (1997). Malignant tumors of the breast.
The nucleotide sequence of the mouse metadherin cDNA has been depos-
In Cancer: Principles and Practice of Oncology (Philadelphia: Lippincott-
ited in GenBank and received accession number AY553638. Raven), pp. 1557–1616.
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